These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6683542)

  • 41. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications.
    Jaspart S; Piel G; Delattre L; Evrard B
    Expert Opin Drug Deliv; 2005 Jan; 2(1):75-87. PubMed ID: 16296736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The importance of selective analytical techniques in bioequivalence testing.
    Lapka R; Ulc I; Kakác B; Rejholec V
    Pharmazie; 1988 Jan; 43(1):50-1. PubMed ID: 3375307
    [No Abstract]   [Full Text] [Related]  

  • 43. Optimum allocation of treatments for Welch's test in equivalence assessment.
    Dette H; Munk A
    Biometrics; 1997 Sep; 53(3):1143-50. PubMed ID: 9333344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating drug solubility in the gastrointestinal tract.
    Dressman JB; Vertzoni M; Goumas K; Reppas C
    Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Consumer protection or self-interest?].
    Heinzl S
    Med Monatsschr Pharm; 2003 Apr; 26(4):109-10. PubMed ID: 12722524
    [No Abstract]   [Full Text] [Related]  

  • 46. Development and validation of a dissolution test for a once-a-day combination tablet of immediate-release cetirizine dihydrochloride and extended-release pseudoephedrine hydrochloride.
    Likar MD; Mansour HL; Harwood JW
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):543-51. PubMed ID: 15975755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonlinear in vitro-in vivo correlations.
    Mendell-Harary J; Dowell J; Bigora S; Piscitelli D; Butler J; Farrell C; Devane J; Young D
    Adv Exp Med Biol; 1997; 423():199-206. PubMed ID: 9269496
    [No Abstract]   [Full Text] [Related]  

  • 48. [Improvement of the absorption of the active substance 2'-hydroxy-5'-methyllaurophenoxamine (FLM 5011) with prodrugs and preparations].
    Tscheuschner C; Neubert R; Fürst W; Lücke L; Fries G
    Pharmazie; 1993 Sep; 48(9):681-4. PubMed ID: 8234402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A confirmatory strategy for therapeutic equivalence trials.
    Kieser M
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):388-90. PubMed ID: 7582393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of testing times and critical values in sequential equivalence testing.
    Müller HH; Schäfer H
    Stat Med; 1999 Jul; 18(14):1769-88; discussion 1789. PubMed ID: 10407247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bioavailability and the assessment of bioequivalence in the control of pharmaceutical preparations].
    Ciranni Signoretti E
    Ann Ist Super Sanita; 1982; 18(3):547-50. PubMed ID: 7187843
    [No Abstract]   [Full Text] [Related]  

  • 53. Release of drugs in vitro from different dermatological preparations.
    Bramanti G; Pisaturo G; Mazzi G; Mura P; Papini P
    Boll Chim Farm; 1980 Dec; 119(12):738-44. PubMed ID: 7225233
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic risks associated with pharmaceutical alternatives.
    N Engl J Med; 1986 Sep; 315(13):834. PubMed ID: 3748098
    [No Abstract]   [Full Text] [Related]  

  • 55. An analysis of the applications of dissolution efficiency.
    Vaughan DP; Tucker GT
    J Pharm Pharmacol; 1976 Dec; 28(12):932-3. PubMed ID: 12276
    [No Abstract]   [Full Text] [Related]  

  • 56. Letter: Bioavailability--a problem in equivalence.
    Hagans JA
    Biometrics; 1975 Jun; 31(2):585. PubMed ID: 1174619
    [No Abstract]   [Full Text] [Related]  

  • 57. The in vitro availability of some barbituric acid derivatives and its correlation to solubility parameter.
    Khalil SA; Abdallah OY; Moustafa MA
    Pharm Acta Helv; 1983; 58(11):307-13. PubMed ID: 6647493
    [No Abstract]   [Full Text] [Related]  

  • 58. Bioavailability--a problem in equivalence.
    Metzler CM
    Biometrics; 1974 Jun; 30(2):309-17. PubMed ID: 4833140
    [No Abstract]   [Full Text] [Related]  

  • 59. [Biopharmacy. I. Concept and definition of therapeutic equivalency].
    Cadorniga R; Arias I
    Boll Chim Farm; 1973 Sep; 112(9):586-95. PubMed ID: 4786707
    [No Abstract]   [Full Text] [Related]  

  • 60. The mean dissolution time depends on the dose/solubility ratio.
    Rinaki E; Dokoumetzidis A; Macheras P
    Pharm Res; 2003 Mar; 20(3):406-8. PubMed ID: 12669960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.